Magnesium
Magnesium produces consistent, modest effects across an unusually wide range of endpoints: blood pressure -2.81 mmHg per Argeros 2025, HbA1c -0.73% in T2DM per Asbaghi 2022, sleep onset latency -17 min per Mah 2021, and migraine OR 0.20 per Chiu 2016. Approximately 50% of US adults are deficient.
Magnesium scored 7.2 / 10 (💪 Strong recommend) on the BioHarmony scale as a Substance → Vitamin / Mineral / Nutrient.
What It Is
Magnesium is a foundational dietary mineral and a cofactor in over 600 enzymatic reactions, including ATP utilization, glucose metabolism, vitamin D activation, and NMDA receptor function. Approximately 50% of US adults fall below the recommended daily allowance per NHANES analyses, with higher deficiency rates in PPI users, athletes, vegetarians, the elderly, type 2 diabetics, and post-bariatric-surgery populations. Modern industrial agriculture, food processing, and PPI-class medications all contribute to the population-scale deficiency.
The supplemental form matters more for magnesium than for almost any other nutrient. Glycinate (bisglycinate) is the community default for sleep and anxiety due to neutral GI tolerance and high bioavailability. Threonate is the only form with documented brain magnesium elevation per Slutsky 2010, reserved for cognitive applications. Malate provides daytime energy via Krebs-cycle co-substrate. Citrate is general-purpose with mild osmotic laxative effect. Ionic forms like RNA Reset ReMag bypass GI tolerance for sensitive users. Oxide is approximately 4% bioavailable in a single oral dose and is best avoided unless used as a deliberate laxative.
Modern RCT evidence is broad and consistent: blood pressure reduces 2 to 8 mmHg depending on baseline status, HbA1c drops 0.73% in T2DM patients with deficiency, sleep onset accelerates 17 minutes in elderly users, migraine frequency falls 80% in deficient migraineurs, and PHQ-9 depression scores drop 6 points in 2 weeks in Tarleton 2017 open-label work. Effects concentrate in deficient subjects; already-replete users see modest benefit.
Terminology
- Elemental magnesium: the actual magnesium content of a supplement, distinct from the total compound weight (e.g. magnesium glycinate is approximately 14% elemental Mg by weight)
- Glycinate / bisglycinate: magnesium chelated to glycine; community default for sleep and anxiety; best GI tolerance
- Threonate (L-threonate, Magtein): patented form with documented brain magnesium elevation; cognitive applications only; industry-funded evidence base
- Malate: magnesium chelated to malic acid; Krebs-cycle co-substrate; daytime energy applications
- Ionic / pico-ionic: solution-form magnesium chloride at sub-nanometer particle size (RNA Reset ReMag is canonical); rapid absorption without GI strain
- TRPM6 / TRPM7: intestinal magnesium channels; polymorphisms alter absorption efficiency
- NMDA antagonism: voltage-dependent blockade of glutamate excitotoxicity; underlies anxiety and migraine effects
- AAN level B: American Academy of Neurology evidence rating for migraine prevention; magnesium qualifies
- EFSA UL: European Food Safety Authority supplemental upper limit (250 mg/day, tied to laxation not toxicity)
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 6 routes and 6 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral capsule or tablet | Glycinate / bisglycinate (best tolerated, neutral GI) | 200-400 mg elemental, 1-2 doses/day | 200-600 mg elemental |
| Oral powder or capsule | L-Threonate (Magtein-patented; CSF penetration) | 1,000-2,000 mg compound (144-288 mg elemental) | Same; sometimes split AM + PM |
| Oral capsule | Malate (Krebs-cycle co-substrate; daytime energy) | 1,000-2,000 mg compound (100-200 mg elemental) | Same |
| Oral liquid (ionic) | Ionic / pico-ionic (RNA Reset ReMag is canonical) | 200-400 mg elemental, sipped throughout the day | Same; up to 600 mg in athletes |
| Topical (chloride spray or oil) | Magnesium chloride solution or Epsom bath | Dermal absorption magnitude debated; user experience consistent | 2-3 sprays (50-100 mg equivalent) topically; Epsom 1-2 cups in bath |
| Oral capsule | Citrate (general-purpose; mild laxative) | 200-400 mg elemental | Same |
Protocols
Sleep and anxiety (community default) Mixed
- Dose
- 200-400 mg glycinate elemental
- Frequency
- 30-60 min pre-bed, daily
- Duration
- Indefinite
Stacks with taurine 1-3 g, glycine 3 g, apigenin 50 mg for complete GABAergic support.
Migraine prevention Clinical
- Dose
- 300-600 mg/day elemental (glycinate or citrate)
- Frequency
- Daily, split 2x
- Duration
- Minimum 8 weeks for measurable frequency reduction
Stacks with riboflavin 400 mg and CoQ10 200 mg per Mauskop AAN level B framework.
Depression adjunct Clinical
- Dose
- 248 mg elemental (glycinate or chloride)
- Frequency
- Daily
- Duration
- Minimum 2 weeks for PHQ-9 response
[Tarleton 2017](https://pubmed.ncbi.nlm.nih.gov/28654669/) RCT dosing. Open-label design; combines additively with SSRI under supervision.
Blood pressure Clinical
- Dose
- 300-500 mg elemental
- Frequency
- Daily, split 2-3x
- Duration
- 8+ weeks
Per [Argeros 2025](https://pubmed.ncbi.nlm.nih.gov/41000008/) updated meta. Effect amplified in treated hypertensives (-7.68 mmHg SBP) and hypomagnesemics (-5.97 mmHg SBP).
Cognitive (brain-specific) Mixed
- Dose
- 2,000 mg threonate (288 mg elemental)
- Frequency
- Daily, often split AM + PM
- Duration
- 8-12 weeks for cognitive endpoints
[Slutsky 2010](https://pubmed.ncbi.nlm.nih.gov/20152124/) mechanism. Premium form; reserve for cognitive goals specifically. Industry-funded evidence base.
Athletic / endurance Mixed
- Dose
- 400-600 mg elemental
- Frequency
- Daily during training blocks
- Duration
- Ongoing
Replaces sweat losses. Malate or glycinate. Ionic forms (RNA Reset) particularly popular in endurance communities.
How this score is calculated →
Upside contribution: 3.85
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.8 | 0.950 | |
| Breadth of Benefits | 15% | 4.5 | 0.675 | |
| Evidence Quality | 25% | 4.0 | 1.000 | |
| Speed of Onset | 10% | 3.5 | 0.350 | |
| Durability | 10% | 3.0 | 0.300 | |
| Bioindividuality Upside | 15% | 3.8 | 0.570 | |
| Total | 3.845 |
Upside Rationale
Magnesium has its best upside when the user matches Magnesium to the evidence-backed lane instead of treating it as a broad wellness shortcut. The upside is breadth with modest but repeatable effects. Magnesium touches nerve signaling, muscle contraction, glucose handling, blood pressure, mood, sleep, and ATP biology. The best use is correcting a common mineral bottleneck, not expecting one capsule to override diet and stress. The most useful anchors are Argeros 2025 and Asbaghi 2022, because they explain both the signal and the boundary around that signal. For readers, the so-what is simple: Magnesium is worth considering when the expected benefit can be observed in a concrete marker, symptom, lab, or performance measure. Magnesium is weaker when the goal is vague optimization with no baseline and no follow-up.
Efficacy (3.8/5.0). Magnesium delivers consistent but modest effects across an unusually wide range of endpoints: blood pressure (-2.81 to -7.68 mmHg per Argeros 2025), glycemic control (HbA1c -0.73% per Asbaghi 2022), sleep onset latency (-17 minutes per Mah 2021), depression (PHQ-9 -6.0 per open-label Tarleton 2017), and migraine frequency (OR 0.20 per Chiu 2016). No single endpoint is transformative, but the consistency across so many systems is remarkable. Effects amplify in deficient subjects (~50% of US adults) and attenuate in already-replete populations.
Breadth of benefits (4.5/5.0). Few supplements span as many systems with consistent evidence per de Baaij et al. 2015: cardiovascular, glycemic, sleep, mood, anxiety, migraine, bone density, mitochondrial energy, athletic recovery, HPA axis modulation, and parasympathetic support via HRV. The post-cardiac-surgery atrial fibrillation reduction in Salaminia 2018 (NNT 7) and the elderly physical-performance signal in Veronese 2016 extend the breadth into surgical and geriatric care. The mechanism (cofactor in 600+ enzymatic reactions plus NMDA antagonism plus vascular smooth muscle relaxation) is conserved across tissues.
Evidence quality (4.0/5.0). Strong evidence base with multiple independent meta-analyses across BP, glycemic control, sleep, depression, and migraine. The threonate-specific evidence carries a 0.3-point integrity adjustment: every L-threonate human RCT to date is funded by Magtein/Magceutics-affiliated researchers, and the Hausenblas 2024 sleep RCT required a corrigendum for undisclosed COI per Agent 5 verification. The broader Mg evidence base across other forms is independent and robust. No Cochrane review on Mg + depression or cardiovascular outcomes exists; pregnancy Cochrane (Makrides) shows null in updated analysis.
Speed of onset (3.5/5.0). Sleep effects within days per Held et al. 2002; anxiety and stress effects within 1-2 weeks; cardiovascular and glycemic responses 4-12 weeks per Zhang 2016 and Fang 2016; bone density 6-12 months. Form bioavailability via Pardo et al. 2021 confirms organic chelates outperform oxide for absorption-rate purposes. Mechanistically fast for the symptom-level outcomes (NMDA antagonism, vasodilation) and slower for tissue-level adaptations (bone matrix, insulin sensitivity).
Durability (3.0/5.0). Effects fade on cessation as serum and tissue levels return to dietary baseline. The intervention is functionally a maintenance dependency for the deficient majority: the gains persist as long as supplementation continues, then revert. Bone-stored magnesium (60% of total body Mg) buffers short interruptions of weeks; longer cessation reverts to baseline deficiency status.
Bioindividuality (3.8/5.0). Approximately 50% of US adults are deficient and respond strongly to repletion. TRPM6/7 polymorphisms alter intestinal absorption. PPI users absorb less. Athletes and those with high sweat losses have higher requirements. Already-replete subjects see minimal additional benefit, though specific use cases (sleep with glycinate, threonate for cognition) can deliver targeted gains in repletion-independent fashion. The combined deficient + targeted-use population covers approximately 60-70% of typical adults.
Downside contribution: 1.62 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 1.2 | 0.360 | |
| Side Effect Profile | 15% | 1.3 | 0.195 | |
| Financial Cost | 5% | 1.5 | 0.075 | |
| Time/Effort Burden | 5% | 1.0 | 0.050 | |
| Opportunity Cost | 5% | 1.0 | 0.050 | |
| Dependency / Withdrawal | 15% | 1.5 | 0.225 | |
| Reversibility | 25% | 1.0 | 0.250 | |
| Total | 1.205 | |||
| Harm subtotal × 1.4 | 1.442 | |||
| Opportunity subtotal × 1.0 | 0.175 | |||
| Combined downside | 1.617 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.277 |
Downside Rationale
Magnesium's main downside is not one isolated risk; it is the mismatch between marketing certainty and the actual evidence base. The downside is form, dose, and kidney context. Magnesium oxide can be poorly tolerated, high doses can cause diarrhea, and kidney disease raises safety stakes. Medication spacing matters for thyroid drugs, bisphosphonates, and certain antibiotics. Mah 2021 is the anchor that keeps the safety discussion honest, while Argeros 2025 helps define where the benefits are strongest. The practical move is to treat Magnesium as a targeted experiment, not a default habit. That means checking contraindications, product quality, dose, medication conflicts, and the opportunity cost of skipping better-supported basics before assigning Magnesium a permanent role.
Safety risk (1.2/5.0). Worst-case safety risk is essentially zero in healthy renal function. Decades of population-scale data show only GI laxation as a common oral side effect. The body has a built-in safety valve: diarrhea occurs well before serum levels approach dangerous territory. Severe hypermagnesemia (cardiac arrhythmia, respiratory depression) clusters exclusively in advanced chronic kidney disease (eGFR below 30), bowel obstruction, or massive overdose. Three significant contraindications: severe CKD requires nephrologist supervision; bowel obstruction is absolute; myasthenia gravis is frequently missed in screening. Slight 0.2 elevation above the cleanest-safety-profile floor reflects the CKD population caveat.
Side effect profile (1.3/5.0). GI laxation is the only common side effect, dose-dependent and form-dependent. Oxide and sulfate hit laxation thresholds at 250-350 mg; citrate at 300-400 mg; glycinate and threonate rarely produce GI effects at standard doses. Ionic forms (RNA Reset ReMag) bypass GI tolerance entirely. No organ toxicity at therapeutic oral doses. No psychiatric, cardiovascular, hepatic, or endocrine adverse signals across the full evidence base in users with normal renal function.
Financial cost (1.5/5.0). Glycinate $10-20/month at 400 mg/day; threonate (Magtein-licensed) $30-45/month; ionic forms (RNA Reset ReMag) $25-35/month; oxide near-free but poor bioavailability. Multi-form stacks (glycinate + threonate + malate) for users targeting multiple goals run $40-60/month combined. Among the more affordable supplements per evidence delivered, especially for the cardiovascular and metabolic indications.
Time / effort burden (1.0/5.0). One to two doses daily depending on form and goal; capsules, powder, or liquid all functionally equivalent within a form class. Topical chloride spray for acute muscle tension adds zero practical effort. No timing complexity beyond evening dosing for sleep applications. Effort is essentially zero relative to outcomes.
Opportunity cost (1.0/5.0). Does not crowd out other interventions. Stacks with vitamin D3+K2, taurine, glycine, B6, omega-3, potassium without conflict. The PPI long-term depletion interaction is a concern only for users on chronic PPIs, and the answer is co-supplementation rather than substitution. Effectively zero displacement of other interventions.
Dependency / withdrawal (1.5/5.0). Functional dependency for the deficient majority: stopping supplementation returns serum and tissue magnesium toward dietary baseline within weeks to months. Bone-stored Mg buffers short cessation periods. No addiction signal, no withdrawal syndrome, no rebound. Dependency rating reflects the maintenance pattern rather than acute pharmacological reliance.
Reversibility (1.0/5.0). Fully reversible at the pharmacological level. Stopping returns magnesium status to dietary baseline within weeks to months. No surgical procedures, no permanent biochemical changes, no enduring effects on tissue function or genetic expression beyond the sustained-supplementation period. Sits at the most-reversible end of the supplementation spectrum.
Verdict
Magnesium is a 7.2/10 fit for people with low intake, stress load, poor sleep, blood-pressure concerns, migraines, or glucose issues who want a practical mineral correction, not a single fix for every symptom tied to stress or metabolism. The cleanest evidence anchors are Argeros 2025, which found systolic blood pressure fell 2.81 mmHg overall, and Asbaghi 2022, which found HbA1c improvement in type 2 diabetes trials. Mah 2021 adds useful context: found sleep-onset latency improved in older adults. The practical gap is the same one that shows up across the report: mechanism and early outcomes are more convincing than broad real-world certainty. In practice, Magnesium belongs after the basics, works best when the target is specific, and deserves tracking around benefits, side effects, interactions, and cost before it becomes a standing protocol.
✅ Best for: Adults with confirmed or suspected deficiency (approximately 50% of US population per NHANES). Anyone targeting sleep quality, anxiety reduction, blood pressure support, depression augmentation, migraine prevention, or athletic recovery. Vegetarians, athletes with high sweat losses, PPI users (chronic depletion), elderly users (absorption decline plus polypharmacy), and post-bariatric-surgery populations. Form selection matters: glycinate or ionic for sleep and anxiety; threonate for cognitive applications; malate for daytime energy; topical chloride for acute muscle tension; citrate for general-purpose plus mild constipation relief.
❌ Avoid if: You have advanced chronic kidney disease (eGFR below 30) without nephrologist supervision (oral supplementation can drive hypermagnesemia in renal failure). You have active bowel obstruction (osmotic effect can worsen the obstruction). You have myasthenia gravis (NMJ blockade risk even at low doses). You take chronic high-dose digoxin (hypomagnesemia potentiates toxicity, but supplementation should be physician-monitored). You require strict drug timing for bisphosphonates, tetracyclines, or fluoroquinolones (chelation; separate by 2-3 hours). You expect dramatic single-dose effects (the intervention is a slow nutritional correction, not an acute pharmacological lever for already-replete users).
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Sleep Quality: 8.6/10
Score: 8.6/10Magnesium sleep quality earns 8.6/10 because Mah 2021 anchors the most relevant signal. Magnesium fits sleep quality when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score stays bounded because effects are usually modest and depend on baseline intake, form, dose, kidney function, and the outcome tracked. In practice, Magnesium is most defensible when someone tracks sleep latency, blood pressure, glucose, mood, cramps, migraine frequency, bowel tolerance, and medication spacing instead of relying on a vague before-and-after feeling. Magnesium is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a foundational mineral experiment with clear stop rules.
Cardiovascular: 8.0/10
Score: 8.0/10Magnesium cardiovascular earns 8.0/10 because Argeros 2025 anchors the most relevant signal. Magnesium fits cardiovascular when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score stays bounded because effects are usually modest and depend on baseline intake, form, dose, kidney function, and the outcome tracked. In practice, Magnesium is most defensible when someone tracks sleep latency, blood pressure, glucose, mood, cramps, migraine frequency, bowel tolerance, and medication spacing instead of relying on a vague before-and-after feeling. Magnesium is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a foundational mineral experiment with clear stop rules.
Mood / Emotional Regulation: 7.6/10
Score: 7.6/10Magnesium mood earns 7.6/10 because Tarleton 2017 anchors the most relevant signal. Magnesium fits mood when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score stays bounded because effects are usually modest and depend on baseline intake, form, dose, kidney function, and the outcome tracked. In practice, Magnesium is most defensible when someone tracks sleep latency, blood pressure, glucose, mood, cramps, migraine frequency, bowel tolerance, and medication spacing instead of relying on a vague before-and-after feeling. Magnesium is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a foundational mineral experiment with clear stop rules.
Mitochondrial: 7.6/10
Score: 7.6/10Magnesium mitochondrial earns 7.6/10 because de Baaij 2015 anchors the most relevant signal. Magnesium fits mitochondrial when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score stays bounded because effects are usually modest and depend on baseline intake, form, dose, kidney function, and the outcome tracked. In practice, Magnesium is most defensible when someone tracks sleep latency, blood pressure, glucose, mood, cramps, migraine frequency, bowel tolerance, and medication spacing instead of relying on a vague before-and-after feeling. Magnesium is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a foundational mineral experiment with clear stop rules.
Anxiety: 7.0/10
Score: 7.0/10Magnesium anxiety earns 7.0/10 because Tarleton 2017 anchors the most relevant signal. Magnesium fits anxiety when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score stays bounded because effects are usually modest and depend on baseline intake, form, dose, kidney function, and the outcome tracked. In practice, Magnesium is most defensible when someone tracks sleep latency, blood pressure, glucose, mood, cramps, migraine frequency, bowel tolerance, and medication spacing instead of relying on a vague before-and-after feeling. Magnesium is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a foundational mineral experiment with clear stop rules.
Blood Sugar / Glycemic Control: 7.6/10
Score: 7.6/10Magnesium blood sugar earns 7.6/10 because Asbaghi 2022 anchors the most relevant signal. Magnesium fits blood sugar when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score stays bounded because effects are usually modest and depend on baseline intake, form, dose, kidney function, and the outcome tracked. In practice, Magnesium is most defensible when someone tracks sleep latency, blood pressure, glucose, mood, cramps, migraine frequency, bowel tolerance, and medication spacing instead of relying on a vague before-and-after feeling. Magnesium is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a foundational mineral experiment with clear stop rules.
Metabolic Health: 7.0/10
Score: 7.0/10Magnesium metabolic health earns 7.0/10 because Asbaghi 2022 anchors the most relevant signal. Magnesium fits metabolic health when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score stays bounded because effects are usually modest and depend on baseline intake, form, dose, kidney function, and the outcome tracked. In practice, Magnesium is most defensible when someone tracks sleep latency, blood pressure, glucose, mood, cramps, migraine frequency, bowel tolerance, and medication spacing instead of relying on a vague before-and-after feeling. Magnesium is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a foundational mineral experiment with clear stop rules.
Bone / Joint Health: 7.0/10
Score: 7.0/10Magnesium bone joint earns 7.0/10 because de Baaij 2015 anchors the most relevant signal. Magnesium fits bone joint when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score stays bounded because effects are usually modest and depend on baseline intake, form, dose, kidney function, and the outcome tracked. In practice, Magnesium is most defensible when someone tracks sleep latency, blood pressure, glucose, mood, cramps, migraine frequency, bowel tolerance, and medication spacing instead of relying on a vague before-and-after feeling. Magnesium is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a foundational mineral experiment with clear stop rules.
Energy / Fatigue: 7.0/10
Score: 7.0/10Magnesium energy earns 7.0/10 because de Baaij 2015 anchors the most relevant signal. Magnesium fits energy when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score stays bounded because effects are usually modest and depend on baseline intake, form, dose, kidney function, and the outcome tracked. In practice, Magnesium is most defensible when someone tracks sleep latency, blood pressure, glucose, mood, cramps, migraine frequency, bowel tolerance, and medication spacing instead of relying on a vague before-and-after feeling. Magnesium is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a foundational mineral experiment with clear stop rules.
Stress / Resilience: 7.0/10
Score: 7.0/10Magnesium stress resilience earns 7.0/10 because de Baaij 2015 anchors the most relevant signal. Magnesium fits stress resilience when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score stays bounded because effects are usually modest and depend on baseline intake, form, dose, kidney function, and the outcome tracked. In practice, Magnesium is most defensible when someone tracks sleep latency, blood pressure, glucose, mood, cramps, migraine frequency, bowel tolerance, and medication spacing instead of relying on a vague before-and-after feeling. Magnesium is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a foundational mineral experiment with clear stop rules.
Recovery / Repair: 7.0/10
Score: 7.0/10Magnesium recovery repair earns 7.0/10 because de Baaij 2015 anchors the most relevant signal. Magnesium fits recovery repair when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score stays bounded because effects are usually modest and depend on baseline intake, form, dose, kidney function, and the outcome tracked. In practice, Magnesium is most defensible when someone tracks sleep latency, blood pressure, glucose, mood, cramps, migraine frequency, bowel tolerance, and medication spacing instead of relying on a vague before-and-after feeling. Magnesium is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a foundational mineral experiment with clear stop rules.
HRV / Vagal Tone / Autonomic Balance: 6.6/10
Score: 6.6/10Magnesium hrv vagal tone earns 6.6/10 because de Baaij 2015 anchors the most relevant signal. Magnesium fits hrv vagal tone when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score stays bounded because effects are usually modest and depend on baseline intake, form, dose, kidney function, and the outcome tracked. In practice, Magnesium is most defensible when someone tracks sleep latency, blood pressure, glucose, mood, cramps, migraine frequency, bowel tolerance, and medication spacing instead of relying on a vague before-and-after feeling. Magnesium is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a foundational mineral experiment with clear stop rules.
Endurance / Cardio: 6.6/10
Score: 6.6/10Magnesium endurance cardio earns 6.6/10 because de Baaij 2015 anchors the most relevant signal. Magnesium fits endurance cardio when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score stays bounded because effects are usually modest and depend on baseline intake, form, dose, kidney function, and the outcome tracked. In practice, Magnesium is most defensible when someone tracks sleep latency, blood pressure, glucose, mood, cramps, migraine frequency, bowel tolerance, and medication spacing instead of relying on a vague before-and-after feeling. Magnesium is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a foundational mineral experiment with clear stop rules.
Memory: 6.6/10
Score: 6.6/10Magnesium memory earns 6.6/10 because Slutsky 2010 anchors the most relevant signal. Magnesium fits memory when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score stays bounded because effects are usually modest and depend on baseline intake, form, dose, kidney function, and the outcome tracked. In practice, Magnesium is most defensible when someone tracks sleep latency, blood pressure, glucose, mood, cramps, migraine frequency, bowel tolerance, and medication spacing instead of relying on a vague before-and-after feeling. Magnesium is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a foundational mineral experiment with clear stop rules.
Cognition / Focus: 6.6/10
Score: 6.6/10Magnesium cognition focus earns 6.6/10 because de Baaij 2015 anchors the most relevant signal. Magnesium fits cognition focus when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score stays bounded because effects are usually modest and depend on baseline intake, form, dose, kidney function, and the outcome tracked. In practice, Magnesium is most defensible when someone tracks sleep latency, blood pressure, glucose, mood, cramps, migraine frequency, bowel tolerance, and medication spacing instead of relying on a vague before-and-after feeling. Magnesium is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a foundational mineral experiment with clear stop rules.
Acute Pain Relief: 6.6/10
Score: 6.6/10Magnesium acute pain earns 6.6/10 because Chiu 2016 anchors the most relevant signal. Magnesium fits acute pain when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score stays bounded because effects are usually modest and depend on baseline intake, form, dose, kidney function, and the outcome tracked. In practice, Magnesium is most defensible when someone tracks sleep latency, blood pressure, glucose, mood, cramps, migraine frequency, bowel tolerance, and medication spacing instead of relying on a vague before-and-after feeling. Magnesium is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a foundational mineral experiment with clear stop rules.
Frequently Asked Questions
What form of magnesium should I take?
Match the form to the goal. Glycinate (bisglycinate) for sleep, anxiety, and general use is the community default: best tolerated, neutral GI, 200-400 mg elemental/day. Threonate (Magtein-patented) is the only form with brain Mg elevation evidence per Slutsky 2010, used at 1,000-2,000 mg compound for cognitive endpoints. Malate provides daytime energy via Krebs-cycle co-substrate. Citrate is general-purpose with a mild osmotic laxative effect. Ionic forms like RNA Reset ReMag bypass GI tolerance and absorb rapidly. Skip oxide unless using as a deliberate laxative: approximately 4% bioavailable per single dose.
How much magnesium should I take per day?
Standard supplemental range is 200-400 mg elemental/day for sleep, anxiety, and general repletion; the EFSA supplemental upper limit is 250 mg/day (tied to laxation, not toxicity), and the IOM UL is 350 mg/day from non-food sources. Athletes commonly run 400-600 mg/day to replace sweat losses. Threonate cognitive protocols use 1,000-2,000 mg of the compound, equivalent to 144-288 mg elemental. Pregnancy RDA increases to 350-400 mg total intake. PPI users and post-bariatric patients have higher requirements. Always screen renal function before sustained high-dose protocols.
Can magnesium really cause kidney problems?
Not in healthy renal function. The Cochrane safety reviews and decades of population-scale data confirm that oral magnesium supplementation produces only GI laxation as a common side effect in adults with normal kidneys. The body has a built-in safety valve: diarrhea occurs well before serum levels approach dangerous territory. Severe hypermagnesemia (cardiac arrhythmia, respiratory depression) clusters exclusively in advanced chronic kidney disease (eGFR below 30), bowel obstruction, or massive overdose. Anyone with CKD stage 3 or higher, myasthenia gravis, or active bowel obstruction should consult their physician before initiating.
Does magnesium really help with sleep?
Yes, with conditions. Mah 2021 meta-analysis showed sleep onset latency reduced by 17.36 minutes; effects strongest in elderly and deficient subjects. Glycinate at 200-400 mg taken 30-60 minutes pre-bed is the community default. Threonate in Hausenblas 2024 and bisglycinate in Schuster 2025 both show RCT-level sleep benefit, though both trials carry industry funding disclosure issues per Agent 5 verification. Stacks well with taurine, glycine, and apigenin for complete GABAergic support. Effect concentrates in deficient subjects; replete users see modest benefit.
What about magnesium for blood pressure?
Modest but reliable. The most current meta-analysis is Argeros 2025, which pooled 38 RCTs (n=2,709) and found SBP reduction of 2.81 mmHg overall. The effect is amplified to -7.68 mmHg SBP in treated hypertensives and -5.97 mmHg SBP in hypomagnesemic subjects. The earlier Zhang 2016 meta-analysis reported similar magnitude. Standard protocol: 300-500 mg elemental/day split, 8+ weeks for measurable effect, glycinate or citrate. Not a replacement for first-line antihypertensives but a real adjunct lever, especially in deficient populations.
Does magnesium prevent migraines?
Yes, supported by AAN level B evidence. Chiu et al. 2016 meta-analysis showed migraine frequency OR 0.20, a roughly 80% reduction in attack incidence. The Mauskop preventive protocol established 300-600 mg elemental per day glycinate or citrate, minimum 8 weeks for frequency reduction. Stacks with riboflavin 400 mg and CoQ10 200 mg in many neurology practices. Mechanism: NMDA antagonism plus cerebral vasodilation. Effect concentrates in patients with low serum or RBC magnesium; testing pre-supplementation helps predict response.
What about ionic magnesium and ReMag?
Ionic magnesium products like RNA Reset ReMag bypass GI tolerance issues and absorb rapidly via passive uptake, which makes them useful for sensitive users and athletes who need higher doses without laxation. Carolyn Dean's pico-ionic positioning is supported by community user reports and a small absorption pilot (PMID 32353962, n=17), but that pilot was funded by a nutrition consulting firm, not independent academic groups. The product remains a defensible choice for users who tolerate other forms poorly or are managing acute deficiency, but the marketing claims about a unique absorption mechanism go beyond what the published evidence supports.
Should I avoid magnesium with certain medications?
Several interactions matter. Bisphosphonates and tetracyclines/quinolones chelate with magnesium; separate by 2-3 hours. Long-term proton pump inhibitor (PPI) use causes serum magnesium depletion via TRPM6/7 colonic absorption impairment per the FDA 2011 warning, with about 25% of cases unresponsive to oral repletion. Potassium-sparing diuretics raise hypermagnesemia risk in CKD. Digoxin toxicity is potentiated by hypomagnesemia, so repletion is often beneficial. Consult a pharmacist or physician if you take any of these chronically. Healthy users on no chronic medications have minimal interaction concern.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| Independent (non-Magtein-funded) large RCT confirms threonate cognitive benefit | Evidence 4.0 to 4.3; Breadth 4.5 to 4.7 | 8.0 / 10 ✅ Top-tier |
| Cochrane review on Mg + depression confirms blinded-RCT effect (currently absent) | Efficacy 3.8 to 4.0; Evidence 4.0 to 4.2 | 7.8 / 10 ✅ Top-tier |
| Long-term cardiovascular outcomes RCT shows mortality benefit | Breadth 4.5 to 4.8; Evidence 4.0 to 4.3 | 8.1 / 10 ✅ Top-tier |
| Deficiency prevalence in US population reverts to historical baseline (food fortification or soil restoration) | Bioindividuality 3.8 to 3.0 | 7.0 / 10 💪 Strong recommend |
| Independent RCT documents adverse cardiovascular signal at high doses in healthy adults | Safety 1.2 to 2.5 | 7.0 / 10 💪 Strong recommend |
Key Evidence Sources
- Argeros C et al. 2025 - Magnesium supplementation and blood pressure: updated meta-analysis, Hypertension. 38 RCTs (n=2,709); SBP -2.81 mmHg overall, -7.68 mmHg treated hypertensives
- Zhang X et al. 2016 - Effects of magnesium supplementation on blood pressure: meta-analysis of 34 RCTs, Hypertension. Foundational BP meta; SBP -2.00 mmHg; effect amplified in hypertensives
- Asbaghi O et al. 2022 - The effects of magnesium supplementation on glycemic control in T2DM: meta-analysis, Critical Reviews in Food Science. HbA1c -0.73% at 500 mg/day in T2DM patients
- Tarleton EK et al. 2017 - Role of magnesium supplementation in the treatment of depression: a randomized clinical trial, PLoS ONE. Open-label RCT (n=126); PHQ-9 -6.0 / GAD-7 -4.5 in 2 weeks; NNT ~3
- Mah J, Pitre T 2021 - Oral magnesium supplementation for insomnia in older adults: meta-analysis, BMC Complementary Medicine. Sleep onset latency -17.36 min in elderly; Cohen's d ~1.1
- Chiu HY et al. 2016 - Effects of intravenous and oral magnesium on reducing migraine: meta-analysis, Pain Physician. Migraine frequency OR 0.20 (80% reduction)
- Slutsky I et al. 2010 - Enhancement of learning and memory by elevating brain magnesium, Neuron. Foundational threonate brain Mg mechanism; rat study; inventor COI
- Hausenblas HA et al. 2024 - Magtein effect on sleep quality: RCT. Threonate sleep RCT; AIDP-funded; corrigendum issued for COI disclosure
- de Baaij JH et al. 2015 - Magnesium in man: implications for health and disease, Physiological Reviews. Foundational physiology review; 600+ enzymatic reactions documented
- Pardo MR et al. 2021 - Bioavailability of magnesium food supplements: systematic review, Nutrition. Form-bioavailability comparison; organic chelates outperform oxide
- Walker AF et al. 2003 - Mg citrate found more bioavailable than other Mg preparations, Magnesium Research. Citrate vs oxide head-to-head; corrected journal attribution per Agent 5 verification
- Veronese N et al. 2016 - Effect of magnesium supplementation on physical performance in elderly: RCT. Physical performance and VO2max in deficient elderly
- Held K et al. 2002 - Oral Mg supplementation reverses age-related neuroendocrine and sleep EEG changes in humans, Pharmacopsychiatry. HPA axis and sleep EEG; foundational sleep mechanism work
- Salaminia S et al. 2018 - Magnesium supplementation and post-cardiac-surgery atrial fibrillation: meta-analysis. Post-surgical AF 46% relative reduction; NNT 7
- Fang X et al. 2016 - Dietary magnesium intake and the risk of cardiovascular disease, type 2 diabetes, and all-cause mortality: dose-response meta-analysis, BMC Med. Cohort meta; 36% lower T2DM risk at highest intake quintile
- Carolyn Dean ReMag absorption pilot study 2020. n=17 industry-funded pilot; supports ionic absorption claims with limited independent validation
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: High
Citations: Argeros 2025, Zhang 2016, Asbaghi 2022, Tarleton 2017, Mah 2021, Chiu 2016, De 2015, Pardo 2021
Pre-RCT-Era Pharmacology and Use
Confidence: Medium
Citations: Epsom 1618, Magnesia 1755, Sjogren 1922
Traditional Medicine Systems
Confidence: Medium
Holistic Evidence for Magnesium
All three lenses converge on magnesium as a foundational nutrient with broad systemic effects, where supplementation primarily corrects widespread modern deficiency rather than producing pharmacological enhancement above baseline. Traditional cultures consumed substantial magnesium loads through mineral water, salt-mineral preparations, and unprocessed plant foods. Modern industrial diets, soil depletion, food processing, and PPI-class medications have produced approximately 50% population deficiency per NHANES. Modern RCT evidence quantifies the repletion benefit: cardiovascular, glycemic, sleep, mood, and migraine endpoints all respond consistently in deficient populations and modestly in already-replete subjects. The honest synthesis: this is nutrient correction at population scale, not therapeutic supplementation.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Magnesium Baseline (pre-protocol)
- RBC Magnesium During | Expected Up
- hs-CRP During | Expected Down
Pulse Dimensions to Watch
- Sleep During | Expected Up | Primary
- Calm During | Expected Up | Primary
- Body During | Expected Up | Secondary
Subjective Signals (Daily Voice Card)
- Muscle Cramping Scale 1-5 | During | Expected Down
- Sleep Depth Scale 1-5 | During | Expected Up
- Loose Stool Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Severe diarrhea or dehydration
- Marked weakness or slow heart rate
Other interventions for Sleep Quality
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.845 − 0.277 = 2.568
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (2.568 / 5) × 5 = 7.6 / 10
Further learning
13 BEST Magnesium Supplements Review 2026: Ultimate Guide
Magnesium is one of the few supplements I take every single day. And multiple forms. This guide explains why.
Why You Have Brittle Bones & Heart Issues: The Shocking Truth About Calcium, Omega-3s, Mag L-Threonate, Vitamin B & Other Supplements You Take
Why do so many people still suffer from weak bones, heart issues, & brain fog despite taking supplements daily? Dr. Carolyn Dean reveals the…
